Affinage

PTGIR

Prostacyclin receptor · UniProt P43119

Length
386 aa
Mass
41.0 kDa
Annotated
2026-06-10
59 papers in source corpus 20 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PTGIR encodes the prostacyclin (PGI2/IP) receptor, a Gsα-coupled GPCR that signals through adenylate cyclase to raise cAMP and activate PKA, a cascade directly demonstrated in platelets where PTGIR agonism inhibits activation, aggregation, and apoptosis by blocking BAD dephosphorylation and reducing caspase-3 activity (PMID:39929746). Across cell types this cAMP/PKA axis is repurposed: in fibroblasts PTGIR activation is antifibrotic, inhibiting fibroblast activation and YAP/TAZ pro-fibrotic transcriptional output, with genetic and pharmacological evidence in renal and intestinal fibrosis (PMID:38062563, PMID:40390655); in monocytes PTGIR controls calprotectin (S100A8/S100A9) expression via adenylate cyclase and STAT3 (PMID:36155972). PTGIR also shapes immunity, promoting Th1 differentiation through cAMP/PKA (PMID:20400695) and acting as an NRF2-induced cell-intrinsic driver of CD8+ T cell exhaustion that limits anti-tumor and anti-viral effector function (PMID:40579556). Receptor abundance is set by transcriptional inputs—direct NF-κB/p65 activation of PTGIR upon TNF-α stimulation (PMID:40390655)—and by CTRP7/Rab5a-mediated internalization that desensitizes pulmonary artery smooth muscle cells to prostacyclin analogues (PMID:40504501). Rare loss-of-function and missense variants, including R212C in the third cytoplasmic loop, impair receptor signaling and are enriched in fibromuscular dysplasia and associated with intimal hyperplasia (PMID:32531060, PMID:18551041).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2008 Medium

    Established that natural PTGIR coding variants alter receptor function and link to human vascular disease, defining a structure-function-pathology axis for the receptor.

    Evidence In vitro overexpression characterization of the R212C third-cytoplasmic-loop variant plus clinical biomarker association in DVT/intimal hyperplasia

    PMID:18551041

    Open questions at the time
    • Single lab; causality between R212C and intimal hyperplasia is associative
    • Mechanism by which the cytoplasmic-loop substitution disrupts Gs coupling not resolved
  2. 2010 High

    Answered whether PTGIR has a cell-intrinsic role in adaptive immunity, showing it promotes Th1 differentiation via cAMP/PKA rather than acting only on vasculature.

    Evidence IP-deficient mice in contact hypersensitivity plus in vitro Th1 assays with IP agonist and PKA inhibitor rescue

    PMID:20400695

    Open questions at the time
    • Downstream transcriptional targets of PKA driving T-bet induction not defined
    • Direct PGI2 source-to-receptor handoff (DC to T cell) inferred from expression, not lineage tracing
  3. 2014 Medium

    Systematically mapped residues required for surface expression versus signaling, distinguishing receptor folding/trafficking determinants from coupling determinants.

    Evidence Error-prone PCR mutagenesis library of >4000 hIP mutants with NGS validation, surface-expression and functional assays

    PMID:24886841

    Open questions at the time
    • Individual residue mechanisms not dissected
    • No structural model linking mutated residues to ligand binding or G-protein interface
  4. 2020 Medium

    Extended PTGIR signaling to innate antimicrobial control by linking the receptor to cytoskeletal and MAPK regulation of pathogen uptake.

    Evidence Macrophage Brucella internalization assays with selexipag, F-actin and p38α MAPK readouts, in vivo mouse challenge

    PMID:33091457

    Open questions at the time
    • Connection between cAMP/PKA and F-actin/p38α not established
    • Single lab
  5. 2021 High

    Provided human genetic evidence that PTGIR loss-of-function causes vascular pathology, elevating prior variant associations to disease enrichment.

    Evidence Exome/targeted sequencing with burden testing against gnomAD plus transient-overexpression functional characterization of Q163X, P17RfsX6, L67P variants in FMD/SCAD patients

    PMID:32531060

    Open questions at the time
    • Tissue/cell type in which receptor loss drives FMD not pinpointed
    • Functional assays performed in heterologous overexpression, not patient vessels
  6. 2022 High

    Defined a defined intracellular signaling route (adenylate cyclase/STAT3) by which PTGIR controls a specific inflammatory output in human monocytes.

    Evidence Lentiviral overexpression and siRNA knockdown in THP-1 and hiPSC-derived monocytes with pathway inhibitors and RNA-seq

    PMID:36155972

    Open questions at the time
    • How adenylate cyclase signaling converges on STAT3 not mechanistically resolved
    • In vivo relevance of monocyte calprotectin regulation untested
  7. 2023 High

    Established PTGIR as an antifibrotic receptor acting on fibroblasts, defining the cellular target of prostacyclin's protective effect in fibrosis.

    Evidence Global, fibroblast-specific Ptgir-KO and Ptgis-KO mice with pharmacological agonist rescue and human CKD scRNA-seq

    PMID:38062563

    Open questions at the time
    • Downstream transcriptional program suppressing fibroblast activation not defined here
    • Whether the effect generalizes beyond kidney addressed only later
  8. 2024 Medium

    Identified PTGIR as the NRF2-regulated effector linking oxidative-stress signaling to CD8+ T cell exhaustion, nominating it as an immune checkpoint.

    Evidence Conditional KEAP1 deletion and PTGIR silencing with transcriptional profiling in chronic infection and tumor models (preprint)

    PMID:38979360

    Open questions at the time
    • Preprint; corroborated by companion paper but key claims awaited peer review
    • How PTGIR signaling reprograms T cell metabolism toward exhaustion not detailed
  9. 2025 High

    Confirmed PTGIR as a cell-intrinsic, NRF2-dependent regulator of CD8+ T cell exhaustion whose silencing restores effector function.

    Evidence KEAP1 deletion and PTGIR silencing with cytokine assays across chronic infection and cancer models

    PMID:40579556

    Open questions at the time
    • Endogenous PGI2 source acting on exhausting T cells in vivo not identified
    • Whether PTGIR blockade synergizes with existing checkpoint therapy untested here
  10. 2025 High

    Resolved the transcriptional control of PTGIR and its antifibrotic mechanism in fibroblasts, placing the receptor in an NF-κB-induced YAP/TAZ-inhibitory pathway disrupted in disease.

    Evidence Dual-luciferase and Cut&Run for p65-driven PTGIR transcription, primary intestinal fibroblasts, chronic colitis model, patient serum PGI2

    PMID:40390655

    Open questions at the time
    • Mechanistic link between PTGIR/cAMP signaling and YAP/TAZ phosphorylation not detailed
    • Reconciliation of NF-κB-driven PTGIR with TGF-β-suppressed PTGIS in vivo incomplete
  11. 2025 High

    Demonstrated post-translational control of PTGIR via CTRP7/Rab5a-mediated internalization, explaining loss of prostacyclin-analogue responsiveness in pulmonary hypertension.

    Evidence ChIP for IL-6/CTRP7, Rab5a internalization assay in PASMCs, AAV CTRP7 silencing in hypoxic PH mice with pharmacological readout

    PMID:40504501

    Open questions at the time
    • Structural basis of CTRP7-PTGIR engagement not defined
    • Whether this internalization route operates in non-pulmonary vasculature unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single Gs/cAMP/PKA receptor produces opposing cell-type-specific outcomes—antifibrotic and anti-platelet protection versus pro-exhaustion immunosuppression—remains unresolved.
  • No unified model for context-dependent PTGIR signaling output
  • Structural/biophysical basis of receptor coupling not established
  • Endogenous PGI2 sources for each downstream context not all defined

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 3 GO:0048018 receptor ligand activity 1
Localization
GO:0005886 plasma membrane 2
Pathway
R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 2 R-HSA-109582 Hemostasis 1
Partners
CTRP7IKEPPPDZK1RAB5A

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 PGI2-IP (PTGIR) signaling promotes Th1 differentiation through a cAMP-protein kinase A pathway. IP-deficient mice showed decreased contact hypersensitivity, reduced IFN-γ production, and smaller T-bet+ T cell subset. In vitro Th1 differentiation was enhanced by an IP agonist, and this enhancement was nullified by a PKA inhibitor. PGI synthase was detected in dendritic cells and IP in T cells, suggesting PGI2 produced by dendritic cells acts on IP in T cells. IP-deficient mouse model (contact hypersensitivity), in vitro Th1 differentiation assay with IP agonist and PKA inhibitor, quantitative real-time PCR for cell-type expression Journal of immunology High 20400695
2025 PTGIR is a NRF2-dependent cell-intrinsic regulator of CD8+ T cell exhaustion. NRF2 (activated by KEAP1 deletion) upregulates PTGIR expression in CD8+ T cells. PTGIR signaling impairs T cell metabolism and cytokine production while inducing transcriptional features of exhaustion. Silencing PTGIR expression enhances IFN-γ and granzyme production and limits terminally exhausted (PD-1+TIM-3+) CD8+ T cell development in chronic infection and cancer models. Conditional KEAP1 deletion in CD8+ T cells, PTGIR silencing, transcriptomic profiling, chronic infection and tumor challenge models, cytokine production assays Nature immunology High 40579556
2024 PTGIR is an NRF2-regulated immune checkpoint linking oxidative stress to CD8+ T cell dysfunction. KEAP1 deletion promotes glutathione production but accelerates terminal CD8+ T cell exhaustion. PTGIR was identified as the downstream NRF2-regulated effector; silencing PTGIR restored anti-tumor function of KEAP1-deficient T cells and reduced terminal exhaustion in chronic infection. Conditional KEAP1 deletion, PTGIR silencing, transcriptional profiling, chronic infection and tumor models bioRxivpreprint Medium 38979360
2006 PTGIR (IP receptor) mediates PGI2-dependent pain and inflammation. IP receptor-deficient mice showed 91% reduction in arthritis score in collagen-antibody induced arthritis. A selective IP antagonist reduced pain in a rat osteoarthritis model with efficacy approaching that of diclofenac. These data establish PGI2 as involved in development of chronic inflammation via IP signaling. IP receptor-deficient mice (genetic KO), selective IP antagonist pharmacology in rat OA model (monoiodoacetate injection) and mouse collagen-antibody induced arthritis model The Journal of pharmacology and experimental therapeutics High 16973887
2021 Rare loss-of-function (LoF) mutations in PTGIR are enriched in fibromuscular dysplasia (FMD). LoF variants Q163X and P17RfsX6, and missense variant L67P identified in FMD/SCAD patients, severely impaired hIP receptor function and/or protein expression when characterized by transient overexpression in human cells. The R212C polymorphism was previously shown to be dysfunctional, and additional LoF alleles were found in FMD patients by burden testing. Exome and targeted sequencing, burden testing against gnomAD controls, transient overexpression in human cells to characterize variant signaling and protein expression Cardiovascular research High 32531060
2008 The PTGIR missense polymorphism R212C located in the third cytoplasmic loop is dysfunctional when examined in an in vitro overexpression system, and is associated with intimal hyperplasia in humans. Carriers of R212C had significantly higher intima-media thickness values. Synonymous polymorphisms V53V/S328S were associated with enhanced platelet activation markers (sP-selectin, 11-dehydro-TXB2) in DVT patients. In vitro overexpression system for functional receptor characterization, clinical biomarker measurements (intima-media thickness, sP-selectin, 11-dehydro-TXB2), PTGIR sequencing in DVT patients and controls Pharmacogenetics and genomics Medium 18551041
2022 PTGIR mediates PGI2-triggered CD16- NK-cell differentiation. In vitro, PGI2 produced by PTGIS-overexpressing endometrial stromal cells triggered CD16- NK-cell differentiation through PTGIR in an ESC/NK-cell co-culture system. Treatment with the PTGIR antagonist RO1138452 partially rescued endometriosis progression in a rodent model. ESC/NK-cell co-culture system, PTGIR antagonist (RO1138452) treatment, ptgis-/- rodent model, adoptive transfer of fcgr3-/- NK cells Experimental & molecular medicine Medium 35781537
2023 PTGIR activation on fibroblasts mediates antifibrotic effects of PGI2 in the kidney. PTGIR-deficient mice showed exacerbated renal fibrosis. Fibroblast/myofibroblast-specific deletion of PTGIR aggravated fibrosis. PGI2 analog or selective PTGIR agonist administered after acute injury ameliorated fibrosis via inhibition of fibroblast activation through PTGIR-mediated signaling. PTGIR deficiency blunted the protective effect of PGI2 analog. Ptgis-KO and Ptgir-KO mice, fibroblast-specific Ptgir conditional deletion, pharmacological PTGIR agonist/analog treatment, single-cell RNA-seq of human CKD kidneys Journal of the American Society of Nephrology High 38062563
2025 PTGIR signaling in intestinal fibroblasts inhibits YAP/TAZ pro-fibrotic activity, and this antifibrotic pathway is impaired in Crohn's disease. PTGIR transcription in fibroblasts is directly activated by p65 (NF-κB) upon TNF-α stimulation, while PTGIS is transcriptionally suppressed by TGF-β. PTGIR is expressed in intestinal fibroblasts but barely in epithelial cells. A PTGIR agonist inhibited YAP/TAZ profibrotic function in vitro and reversed intestinal fibrosis in a chronic colitis model in vivo. Dual luciferase reporter and Cut & Run assays for PTGIR/PTGIS transcriptional regulation, primary intestinal fibroblasts, chronic colitis mouse model, ELISA for serum PGI2 in CD patients Journal of Crohn's & colitis High 40390655
2029 PTGIR signaling (via Gsα-coupled receptor activating adenylate cyclase) elevates cAMP, which activates PKA in platelets. Iloprost acting through PTGIR concentration-dependently inhibits platelet activation, aggregation, apoptosis, and in vivo thrombosis. PKA elevation by PTGIR signaling inhibits BAD dephosphorylation and reduces caspase-3 activity to retard platelet apoptosis. Low-dose iloprost (PTGIR agonism) elevates peripheral platelet counts in immune thrombocytopenia by inhibiting platelet apoptosis without affecting platelet function. Iloprost pharmacology in human and mouse platelets, PKA activity assays, Ca2+ measurements, FeCl3-induced thrombosis model, GPIbα antibody-induced ITP model, flow cytometry for apoptosis markers Journal of cellular and molecular medicine Medium 39929746
2015 In porcine endometrial cells, PTGIR activation by iloprost results in cAMP generation and increased expression of FGF-2 and VEGF164 mRNA in stromal (but not luminal epithelial) cells. PTGIR expression is upregulated during the peri-implantation period and is regulated by IL1β, IFNγ, and conceptus-derived factors but not estradiol. In vitro iloprost treatment of luminal epithelial and stromal cells, cAMP assay, qPCR for FGF-2 and VEGF164, endometrial tissue from cyclic and pregnant gilts Theriogenology Medium 26139576
2023 In porcine endometrial endothelial cells, PTGIR activation by iloprost (PGI2 analogue) promotes angiogenesis-related processes including enhanced KDR, FGFR2, and ANGPT2 transcript abundance, increased cell proliferation (mediated by PI3K and mTOR activation), accelerated gap closure, and cell cycle progression. However, iloprost inhibited capillary-like structure formation. Iloprost treatment of porcine endometrial endothelial cells and G1410 cells, siRNA knockdown of PTGIS, proliferation assays, gap closure assay, cell cycle analysis, PI3K/mTOR pathway inhibitors Scientific reports Medium 37644083
2010 BEAS-2B human airway epithelial cells co-express two pharmacologically distinct prostacyclin receptors: the canonical IP receptor (PTGIR) and a novel 'IP2' subtype. siRNA directed against PTGIR blocked taprostene/iloprost-induced transcriptional responses (cAMP response element and glucocorticoid response element reporter activation) but failed to block suppression of CXCL9/CXCL10 chemokine output by taprostene and 15-deoxy-TIC, establishing that chemokine suppression is mediated by the novel IP2 receptor distinct from PTGIR. siRNA knockdown of PTGIR, HEK293 overexpression of recombinant hIP receptor, cAMP accumulation assays, luciferase reporter assays, pharmacological characterization with IP antagonist RO3244794 Molecular pharmacology Medium 21173040
2022 PTGIR expression and signaling in human monocytes (THP-1) controls calprotectin (S100A8/S100A9) expression. Increasing PTGIR expression or stimulating PTGIR signaling increased calprotectin expression in THP-1 and hiPSC-derived monocytes; knockdown or inhibition of PTGIR decreased calprotectin expression. PTGIR-mediated calprotectin regulation is dependent on signaling via adenylate cyclase and STAT3. Lentiviral PTGIR overexpression in THP-1, siRNA knockdown, PTGIR agonist/antagonist pharmacology, hiPSC-derived monocyte validation, RNA-seq, adenylate cyclase and STAT3 pathway inhibitors PLoS genetics High 36155972
2014 High-throughput error-prone PCR mutagenesis of the hIP receptor (PTGIR) identified 18 mutants expressed at the cell surface with impaired receptor function, mapping to 36 distinct residues including several in transmembrane domains. This established structure-function relationships for hIP receptor expression and signaling. Error-prone PCR mutagenesis library of >4000 hIP receptor mutants, next-generation sequencing for library validation, cell-surface expression assays, functional signaling assays PloS one Medium 24886841
2020 PGI2 inhibits Brucella internalization into macrophages via PTGIR signaling, which leads to downregulation of F-actin polymerization and p38α MAPK activity. The PGI2 analogue selexipag acting through PTGIR suppressed immune responses and reduced bacterial burden in Brucella-challenged mice. Bone marrow-derived macrophage and RAW264.7 infection assays, selexipag (PTGIR agonist) pharmacology, F-actin polymerization and p38α MAPK activity measurements, in vivo mouse challenge Developmental and comparative immunology Medium 33091457
2025 CTRP7 reduces PTGIR expression in pulmonary artery smooth muscle cells through Rab5a-mediated receptor internalization, thereby diminishing responsiveness to selexipag (prostacyclin analogue). IL-6 upregulates CTRP7 in PASMCs (confirmed by chromatin immunoprecipitation). Silencing CTRP7 in pulmonary arteries of hypoxic PH mice via AAV restored PTGIR expression and improved selexipag responsiveness. Chromatin immunoprecipitation for IL-6 regulation of CTRP7, RNA-seq of PASMCs, PTGIR internalization assay via Rab5a pathway, AAV-mediated CTRP7 silencing in hypoxic PH mice, IL-6-R neutralizing antibody treatment Cardiovascular research High 40504501
2015 PTGIR gene expression in the human vasculature is transcriptionally regulated by factors responsive to cellular differentiation, estrogen, and low serum-cholesterol. PTGIR interacts with PDZK1 (a multi-PDZ-domain protein essential for reverse-cholesterol transport and endothelialization) and with IKEPP (intestinal and kidney enriched PDZ protein), interactions that impact PTGIR function in the vasculature. Transcriptional regulation studies (trans-acting factor identification), protein interaction studies with PDZK1 and IKEPP (from review summarizing primary experimental work) Prostaglandins & other lipid mediators Low 25936507
2014 In HUVECs overexpressing PGI2 synthase (PGI2S), PTGIR protein is upregulated along with PKA and PKC, correlating with an anticoagulant phenotype. MAPK expression was not altered. These cells showed upregulation of ATIII and PLG and downregulation of FVIII. Lentiviral overexpression of PGI2S in HUVECs, qRT-PCR and western blotting for PTGIR, PKA, PKC, MAPK; ELISA for coagulation factors International journal of molecular sciences Low 24557578
1995 The human PTGIR gene was chromosomally mapped to chromosome 19q13.3 using in situ hybridization. Chromosomal in situ hybridization Genomics Medium 7759114

Source papers

Stage 0 corpus · 59 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2022 Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer. Molecular cancer 140 35717322
2006 Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. The Journal of pharmacology and experimental therapeutics 93 16973887
2006 Developmental regulation of prostacyclin synthase and prostacyclin receptors in the ovine uterus and conceptus during the peri-implantation period. Reproduction (Cambridge, England) 67 16672356
2007 Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma. Pharmacogenetics and genomics 62 17496729
2010 Prostaglandin I2-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity. Journal of immunology (Baltimore, Md. : 1950) 57 20400695
2010 Comprehensive expression analysis of prostanoid enzymes and receptors in the human endometrium across the menstrual cycle. Molecular human reproduction 52 21112968
2011 Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenetics and genomics 38 21052031
2012 Synthesis of prostacyclin and its effect on the contractile activity of the inflamed porcine uterus. Theriogenology 37 23218395
2016 Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta. Pharmacological research 36 26993102
2008 Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. Pharmacogenetics and genomics 34 18551041
2017 Changes in vasoactive pathways in congenital diaphragmatic hernia associated pulmonary hypertension explain unresponsiveness to pharmacotherapy. Respiratory research 29 29115963
1995 Chromosomal localization of the human prostanoid receptor gene family. Genomics 28 7759114
2021 Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. Cardiovascular research 25 32531060
2011 Altered expression of inflammation-related genes in human carotid atherosclerotic plaques. Atherosclerosis 25 22112851
2003 Catalog of 178 variations in the Japanese population among eight human genes encoding G protein-coupled receptors (GPCRs). Journal of human genetics 22 12955588
2022 Hypoxia-hindered methylation of PTGIS in endometrial stromal cells accelerates endometriosis progression by inducing CD16- NK-cell differentiation. Experimental & molecular medicine 21 35781537
2017 Spermatozoa from males with reduced fecundity exhibit differential DNA methylation patterns. Andrology 19 28544631
2014 Transcriptome profiling of natural dichromatism in the annual fishes Nothobranchius furzeri and Nothobranchius kadleci. BMC genomics 19 25183398
2025 The prostacyclin receptor PTGIR is a NRF2-dependent regulator of CD8+ T cell exhaustion. Nature immunology 17 40579556
2024 Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma. Stem cell research & therapy 16 38414067
2010 Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release. Molecular pharmacology 14 21173040
2007 Arginine (CGC) codon targeting in the human prostacyclin receptor gene (PTGIR) and G-protein coupled receptors (GPCR). Gene 14 17481829
2021 Neuromuscular junction-specific genes screening by deep RNA-seq analysis. Cell & bioscience 13 33933147
2019 miR-34b-3p May Promote Antiplatelet Efficiency of Aspirin by Inhibiting Thromboxane Synthase Expression. Thrombosis and haemostasis 13 31266078
2015 Prostacyclin receptors: Transcriptional regulation and novel signalling mechanisms. Prostaglandins & other lipid mediators 13 25936507
1996 Mapping of the genes encoding mouse prostaglandin D, E, and F and prostacyclin receptors. Genomics 12 8833158
2022 Angiogenetic and anti-inflammatory effects of photobiomodulation on bone regeneration in rat: A histopathological, immunohistochemical, and molecular analysis. Journal of photochemistry and photobiology. B, Biology 11 36493717
2020 G Protein-Coupled Receptor Genes, PTGDR1, PTGDR2, and PTGIR, Are Candidate Epigenetic Biomarkers and Predictors for Treated Patients with HPV-Associated Oropharyngeal Cancer. Microorganisms 11 33003642
2022 Prostaglandins and calprotectin are genetically and functionally linked to the Inflammatory Bowel Diseases. PLoS genetics 10 36155972
2020 Prostaglandin I2 (PGI2) inhibits Brucella abortus internalization in macrophages via PGI2 receptor signaling, and its analogue affects immune response and disease outcome in mice. Developmental and comparative immunology 10 33091457
2023 Differential drug response in pulmonary arterial hypertension: The potential for precision medicine. Pulmonary circulation 9 37927610
2014 High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function. PloS one 9 24886841
2015 Prostacyclin receptor (PTGIR) in the porcine endometrium: Regulation of expression and role in luminal epithelial and stromal cells. Theriogenology 8 26139576
2023 Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor. Journal of the American Society of Nephrology : JASN 7 38062563
2024 α7-Nicotinic Acetylcholine Receptor Activation Modulates BV2 Microglial Plasticity via miR-21/TNF-α/NFκB in Oxygen-Glucose Deprivation/Reoxygenation. Journal of molecular neuroscience : MN 6 39718716
2017 Isolation of luteal endothelial cells and functional interactions with T lymphocytes. Reproduction (Cambridge, England) 6 28174320
2024 NRF2-dependent regulation of the prostacyclin receptor PTGIR drives CD8 T cell exhaustion. bioRxiv : the preprint server for biology 5 38979360
2023 Diverse effects of prostacyclin on angiogenesis-related processes in the porcine endometrium. Scientific reports 5 37644083
2022 Prostanoid Signaling in Cancers: Expression and Regulation Patterns of Enzymes and Receptors. Biology 5 35453789
2021 Natural Compounds from Hatikana Extract Potentiate Antidiabetic Actions as Displayed by In Vivo Assays and Verified by Network Pharmacological Tools. BioMed research international 5 34725640
2015 Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. PloS one 5 26630678
2025 Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn's disease via fibroblast-specific YAP/TAZ inhibition. Journal of Crohn's & colitis 4 40390655
2015 Expression of prostaglandin I2 (prostacyclin) receptor in blood of migraine patients: A potential biomarker. Advanced biomedical research 3 26261823
2025 Iloprost Concentration-Dependently Attenuates Platelet Function and Apoptosis by Elevating PKA Activity. Journal of cellular and molecular medicine 2 39929746
2025 Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing. European journal of endocrinology 2 40177881
2025 CTRP7 as a molecular biomarker associating with responsiveness to pulmonary vasodilators: insights from human and animal studies in pulmonary arterial hypertension. Cardiovascular research 2 40504501
2025 Single-cell transcriptomic analysis of the human vascular atlas provides new insights into vasorelaxation redundancy and heterogeneity. Frontiers in cardiovascular medicine 2 40881588
2024 Identification of novel membrane markers in circulating tumor cells of mesenchymal state in breast cancer. Biochemistry and biophysics reports 2 38375422
2024 Evaluating the Predictive Value of a Coagulation-Related Gene Model in Glioma. Turkish neurosurgery 2 38650572
2023 Network and pathway-based analysis of candidate genes associated with esophageal adenocarcinoma. Journal of gastrointestinal oncology 2 36915458
2017 A Report of a Novel Mutation in Human Prostacyclin Receptor Gene in Patients Affected with Migraine. Iranian journal of psychiatry 2 29062375
2025 Identifying causal genes for prostatitis through drug-targeted Mendelian randomization. Scientific reports 1 40447747
2020 MirSNPs in clopidogrel metabolism genes predict cardiovascular disease risk: a case-control study and meta-analysis. Pharmacogenomics 1 33356544
2014 The anticoagulant effect of PGI2S and tPA in transgenic umbilical vein endothelial cells is linked to up-regulation of PKA and PKC. International journal of molecular sciences 1 24557578
2026 Treprostinil reduces blood pressure and aortic inflammation in hypertension. Clinical science (London, England : 1979) 0 42240117
2025 Unraveling the Role of PTGIR in Atrial Fibrillation: Insights From Single-Cell Sequencing and Mendelian Randomization. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0 41292196
2023 Resilience Mediates the Relationship Between Parental Attachment and Posttraumatic Growth in Adolescents: A Longitudinal Study. Disaster medicine and public health preparedness 0 37185263
2022 Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors. Animals : an open access journal from MDPI 0 36077955
2018 Variants in Human Prostacyclin Receptor Gene in Patients with Migraine Headache. Iranian journal of psychiatry 0 30627197

Missed literature

Know a paper Affinage missed for PTGIR? Flag it for the maintainers and the community.

No submissions yet.